Drug Discovery Services Market Size & Share 2026-2035

Drug Discovery Services Market Size

The global drug discovery services market reached USD 19.2 billion in 2025. The market is projected to advance from USD 21.5 billion in 2026 to USD 67.3 billion by 2035, compounding at a CAGR of 13.5% over the forecast period, according to the latest report published by Global Market Insights Inc.

The structural foundation of this growth is the convergence of three reinforcing trends: large pharmaceutical companies are accelerating outsourcing of early-stage discovery work to specialized CROs, the proportion of biological therapeutics in active drug pipelines continues to rise, and artificial intelligence is reshaping the productivity profile of target identification, lead optimization, and candidate validation. Of greater strategic consequence over the medium term is the increasing reliance of mid-size and emerging biotech companies on integrated CRO partnerships a model that deepens revenue visibility for leading service providers and structurally elevates the addressable market above what aggregate R&D spending figures alone would suggest.

Drug Discovery Services Market Trends

AI and Machine Learning Integration Across the Discovery Workflow

Artificial intelligence is reshaping the market at every stage of the value chain, from target identification and molecular docking to lead optimization and ADMET prediction. Machine learning algorithms trained on large bioactivity datasets can identify viable lead candidates in a fraction of the time required by conventional high-throughput screening alone, with published benchmarks indicating reductions in early-stage discovery timelines of 30–40% on comparable programs. The underlying driver is the exponential growth in available biological and chemical data genomics databases, protein structure repositories such as AlphaFold, and accumulated assay results from decades of HTS programs which provide the training substrate for increasingly accurate predictive models. In our Q1 2026 survey of 280 pharmaceutical R&D directors across North America and Europe, 67% indicated that AI-assisted target identification had already been integrated into at least one active discovery program, up from 38% in 2023, signaling a rapid transition from pilot adoption to standard workflow integration.

A concrete example of scaled AI deployment is Evotec SE's EVOiD platform, which integrates proprietary disease models with machine learning to identify novel drug targets and optimize candidates across oncology and CNS programs. By early 2025, the platform had contributed to over 50 active co-discovery partnerships with global pharmaceutical companies, demonstrating the commercial viability of AI-native discovery at scale. The second-order effect is a reconfiguration of CRO talent requirements: computational chemists, bioinformatics specialists, and data scientists are becoming as central to service delivery as traditional medicinal chemists, reshaping hiring priorities and infrastructure investment across the sector.

Structural Shift Toward Outsourcing and Integrated CRO Partnerships

The drug discovery services market is undergoing a fundamental structural shift in how pharmaceutical companies organize their early-stage R&D operations. Large pharma companies which historically maintained extensive internal discovery infrastructure are increasingly disaggregating their pipelines and outsourcing early-stage work to specialized CROs, a pattern that reflects both cost efficiency objectives and the recognition that leading CROs now match or exceed internal capabilities across many service lines. Industry data shows that outsourced drug discovery as a share of total early-stage R&D spend has grown consistently, with CROs now executing a material proportion of hit identification, lead optimization, and candidate validation programs that were previously conducted in-house.

The shift is most pronounced among mid-size biotechs, which operate with lean internal teams and rely on CROs for full-service discovery support including medicinal chemistry, in vitro biology, and DMPK profiling. Charles River Laboratories has extended its integrated platform through capacity expansions and targeted acquisitions, positioning its service offering to accompany clients from early target validation through IND-enabling studies within a single outsourcing relationship. Of greater strategic consequence is the emergence of preferred-provider frameworks, in which pharma companies consolidate outsourcing across two or three CRO partners rather than distributing work transactionally a model that deepens revenue visibility for leading CROs, raises client switching costs, and structurally reinforces concentration among the top tier of the market.

Rising Biologics and Biosimilars Pipeline Driving Service Expansion

• The global drug pipeline has shifted materially toward biological therapeutics, with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and gene therapy constructs representing a dominant and growing share of novel drug approvals. This shift carries direct implications for discovery services: biological therapeutics require a fundamentally different service toolkit compared to small-molecule drugs, encompassing cell line development, recombinant protein production, in vitro biological assays, and specialized bioanalytical methods. CROs that have invested in dedicated biologics discovery infrastructure including mammalian cell culture systems, advanced bioanalytical instrumentation, and in vitro receptor binding platforms are capturing a disproportionate share of outsourcing contracts as pharmaceutical clients advance complex biological candidates.
• Labcorp Drug Development and Pharmaron Beijing have both expanded their biological services capabilities through targeted investments in recombinant protein platforms and large-molecule bioanalysis. Supply chain leads interviewed across Tier-1 biotech companies indicated that 58% were actively expanding their reliance on CROs specifically for biologics discovery by mid-2025, citing the capital intensity of maintaining internal biologics infrastructure as the primary driver. The integration of biosimilar development into CRO service portfolios represents an additional layer of growth, as biologics loss-of-exclusivity events accelerate and both originator companies and biosimilar developers seek external discovery, characterization, and analytical support.

High-Throughput Screening and Laboratory Automation

• High-throughput screening (HTS) and laboratory automation have transitioned from differentiating capabilities to standard infrastructure at leading drug discovery CROs. Modern HTS platforms can process upwards of 100,000 compounds per day, while automated liquid handling, robotic plate management systems, and integrated data capture reduce human error and accelerate dose-response data generation at scale. The economics of automation are consequential: standardized automated workflows reduce per-assay costs substantially, enabling CROs to offer large compound library screening programs at commercially viable pricing for smaller biotech clients that could not previously access high-capacity screening infrastructure. Thermo Fisher Scientific (PPD) deployed a next-generation integrated automation suite at its US discovery facility in October 2024, increasing compound processing throughput by approximately 40% and reducing hit confirmation cycle times. Beyond throughput, standardized automated workflows reduce inter-site variability, enabling clients to split programs across multiple CRO locations without compromising data comparability a practical advantage as distributed drug development becomes the norm.
• Preference among both clinicians and pet owners for treatment protocols with favorable safety and recovery profiles is driving measurable growth in radiotherapy and immunotherapy relative to surgical intervention for select tumor types. Stereotactic body radiation therapy (SBRT), which delivers high-dose radiation in 1–3 fractions, offers a compelling clinical profile for canine nasal tumors, spinal lesions, and select soft tissue sarcomas providing durable local control with minimal procedure-related morbidity compared to surgical resection. The shift is reinforced by improvements in veterinary anesthesia protocols that have reduced the procedural risk ceiling for multi-session radiation courses, making these approaches accessible to older or compromised patients for whom surgery carries elevated perioperative risk. Elekta's convening of a 12-country veterinary radiation oncology symposium in Stockholm in October 2023 reflects growing institutional momentum toward formalizing adaptive radiotherapy frameworks specifically for companion animal oncology an infrastructure development that will support further clinical adoption of minimally invasive radiation approaches through the forecast period.

Drug Discovery Services Market Analysis

By Process

Target Selection

Target selection accounts for 10.3% of global drug discovery services revenues in 2025, representing the earliest and, increasingly, one of the most consequential stages of the discovery value chain in determining downstream program success. This segment encompasses the identification and prioritization of biological targets typically proteins, receptors, or nucleic acid structures whose modulation is hypothesized to produce a therapeutic effect in a defined disease context. Historically, target selection relied on academic literature review, phenotypic screening outcomes, and disease genetics data, but the integration of AI-driven bioinformatics platforms has fundamentally expanded the scope of druggable target space under active investigation.

Companies including WuXi AppTec and Evotec SE have deployed proprietary computational platforms that integrate multi-omics data encompassing genomics, transcriptomics, and proteomics to rank candidate targets by biological validity, disease relevance, and structural tractability, enabling pharmaceutical clients to enter lead identification with higher-confidence starting points. The segment's relatively smaller revenue share reflects its upstream position in the discovery timeline rather than its strategic importance: poor target selection is widely recognized as one of the primary upstream drivers of late-stage clinical attrition, and investment in rigorous AI-augmented target prioritization is increasingly viewed as a cost-effective strategy for improving portfolio-level return on discovery investment.

Target validation

Target validation represents 15.5% of drug discovery services market revenues in 2025, covering the experimental and computational confirmation that a selected biological target is causally implicated in disease and pharmacologically amenable to therapeutic intervention. This segment demands a diverse toolkit including CRISPR-based gene editing, RNA interference, transgenic cell lines, and structural biology techniques such as X-ray crystallography and cryo-electron microscopy to establish target engagement, pathway linkage, and safety feasibility before committing resources to hit identification. The more consequential challenge in target validation is the translation gap between in vitro cellular systems and in vivo disease relevance: CROs that can deploy human-derived models, including patient-derived organoids and hiPSC-based systems, deliver meaningfully higher validation confidence than those relying on conventional immortalized cell lines.

Sygnature Discovery and Pharmaron Beijing have invested in structural biology infrastructure including cryo-EM suites at Pharmaron's Ningbo facility commissioned in December 2024 to support fragment-based screening and structure-guided target validation, directly addressing pharmaceutical client demand for mechanistic confidence prior to large-scale compound screening. Revenue in this segment is growing faster than its current share implies, driven by pharmaceutical companies' recognition that target validation failure remains a primary contributor to late-phase clinical attrition.

Hit-to-Lead Identification and Lead Optimization

Hit-to-lead identification accounts for 24% of process segment revenues in 2025 and represents the stage at which confirmed biological activity is first established across a compound series converting raw screening output into structured chemical matter with defined structure-activity relationships. The segment encompasses primary screening against validated targets using compound libraries ranging from focused sets to diverse collections exceeding one million compounds, followed by hit confirmation, counter-screening for selectivity, and preliminary SAR analysis to identify lead-worthy series. High-throughput screening platforms operated by Charles River Laboratories and Thermo Fisher Scientific (PPD) can process hundreds of thousands of compounds per day, with integrated robotic sample management and AI-driven data interpretation systems accelerating hit confirmation and reducing false-positive rates.

The integration of DNA-encoded chemical library (DEL) technology by several leading CROs has further expanded the hit identification toolkit, enabling rapid interrogation of compound collections orders of magnitude larger than those accessible to conventional HTS. A closer read of procurement patterns reveals that pharmaceutical clients are increasingly requesting integrated computational pre-filtering using virtual screening and machine learning-based activity prediction to enrich compound subsets prior to physical screening, improving hit rates and reducing per-program screening costs.

Lead optimization

Lead optimization is the largest process segment at 28.50% of global drug discovery services revenues in 2025, reflecting its position as the most resource-intensive and iterative stage of the discovery workflow. At this stage, CROs execute repeated cycles of medicinal chemistry design, synthesis, in vitro profiling, and computational modeling to systematically improve candidate compounds across multiple parameters simultaneously including potency, selectivity, metabolic stability, solubility, permeability, and hERG safety liabilities. The iterative nature of the process, combined with the need for integrated computational chemistry, synthetic chemistry, DMPK, and biology capabilities within a tightly coordinated team, favors large integrated CROs that can execute rapid design-make-test-analyze cycles without inter-organizational handoffs. Curia Global's medicinal chemistry platform and Sai Life Sciences' integrated hit-to-candidate capabilities exemplify mid-tier CRO positioning in this segment, serving pharmaceutical clients seeking cost-competitive lead optimization partnerships with strong synthetic chemistry execution. The introduction of free energy perturbation (FEP) calculations, quantum mechanical property predictions, and AI-augmented scaffold hopping tools has materially reduced the number of synthesis-test cycles required to achieve development-grade compound profiles, reducing program timelines and making outsourced lead optimization progressively more cost-effective relative to fully internal programs.

Candidate Validation

Candidate validation contributes 21.70% of process revenues in 2025 and represents the final, highest-stakes stage of preclinical drug discovery in which a lead series is narrowed to a single development candidate supported by sufficient in vivo pharmacology, safety pharmacology, and preliminary ADMET data to justify the submission of an investigational new drug application. Services within this segment are among the most regulated in the discovery portfolio: GLP-compliant toxicology studies, in vivo efficacy studies across validated animal models, and comprehensive bioanalytical characterization must each adhere to regulatory standards set by the FDA, EMA, and national health authorities. Charles River Laboratories, which operates integrated discovery-through-IND service platforms across North America and Europe, leads this segment, with deep GLP toxicology infrastructure and established scientific relationships with regulatory agencies that provide clients with confidence in IND submission success rates. The segment's revenue profile benefits from the expansion of novel therapeutic modalities including PROTAC degraders, covalent inhibitors, and RNA-targeted compounds which each require specialized candidate validation methodologies beyond standard small-molecule preclinical packages.

By Type

Chemistry Services

Chemistry services represent the larger of the two type segments, accounting for 54.6% of global drug discovery services revenues in 2025. This segment encompasses the full spectrum of synthetic and computational chemistry activities deployed in drug discovery, including medicinal chemistry, parallel synthesis, structure-based drug design, process chemistry scale-up, and cheminformatics collectively constituting the core scientific workflow through which drug candidates are designed, synthesized, and refined. The dominance of chemistry services reflects the structural persistence of small-molecule drug discovery as the foundation of pharmaceutical R&D, as well as the breadth of chemistry-dependent activities across all discovery stages from hit identification through candidate validation.

Sai Life Sciences, Aragen Life Sciences, and Curia Global have built competitive positions in this segment by offering high-quality synthetic chemistry execution at cost-competitive rates, drawing outsourcing from North American and European pharmaceutical clients that seek to reduce per-compound synthesis costs without compromising chemical diversity or data quality. At the technology frontier, CROs deploying AI-assisted retrosynthesis platforms and automated flow chemistry synthesis systems are compressing compound turnaround timelines a critical parameter in iterative lead optimization cycles while simultaneously expanding access to structurally complex and novel chemical space. The integration of computational chemistry within chemistry services portfolios has blurred the historical boundary between in silico and wet-lab activities, with leading CROs now offering fully integrated design-make-test cycles from a single team.

Biological Services

Biological services account for 45.40% of global drug discovery services revenues in 2025 and represent the fastest-growing type segment, driven by the sustained shift in the global drug pipeline toward biological therapeutics and the increasing reliance on in vitro and in vivo biological assays to characterize compound activity, selectivity, and mechanism of action. This segment encompasses biochemical and cell-based assay development, in vivo pharmacology, DMPK characterization, biomarker development, recombinant protein and antibody production, and advanced modality-specific platforms for ADCs, bispecific antibodies, and cell and gene therapy candidates. The more consequential growth driver is the expanding application of patient-derived biological models including 3D organoids, co-culture tumor systems, and iPSC-derived neuronal preparations which more faithfully replicate human disease biology than traditional cell lines and support stronger translational confidence. Syngene International invested specifically in biologics-oriented biological services infrastructure at its Bengaluru campus with a dedicated large-molecule discovery block inaugurated in January 2025, while Evotec SE's biology platforms underpin its AI-augmented co-discovery partnerships across CNS and oncology. The convergence of biological services with data science through integrated LIMS systems, automated data analysis pipelines, and AI-driven phenotypic interpretation is elevating the strategic value of this segment beyond traditional assay execution, positioning leading CROs as partners in biological hypothesis generation rather than pure service providers.

By Drug Type

Small-molecule Drugs

Small-molecule drugs account for 58.6% of global drug discovery services revenues in 2025, reflecting the continued centrality of low-molecular-weight synthetic compounds as the dominant modality in active pharmaceutical pipelines despite the structural shift toward biologics. Small molecules remain preferred for oral bioavailability, intracellular target access, manufacturing cost-efficiency, and patient adherence attributes that sustain demand across high-volume therapeutic areas including oncology, CNS disorders, cardiovascular disease, and metabolic conditions. The small-molecule drug discovery services market has been invigorated by the emergence of novel chemical modalities that extend the reach of traditional medicinal chemistry into previously intractable target classes: targeted protein degraders (PROTACs and molecular glues), covalent inhibitors, and macrocyclic compounds are each drawing dedicated outsourcing programs to CROs with specialized synthetic and computational capabilities. Aurigene Pharmaceutical Services and BioDuro-Sundia have established active PROTAC discovery programs, reflecting client demand for CROs capable of executing the more complex synthesis and biophysical characterization workflows these modalities require.

From a pricing standpoint, small-molecule discovery services command variable contract structures depending on program stage: target identification and HTS-stage work is typically transactional and volume-driven, while integrated lead optimization partnerships carry higher per-program value and longer contract durations. The data indicates that AI-designed molecules compounds that have passed through generative chemistry models and virtual ADMET filtering before any physical synthesis are entering active clinical pipelines with increasing frequency, creating a new sub-category of outsourcing demand for CROs equipped to validate and advance computationally originated chemical matter. On a unit-economics basis, AI-augmented small-molecule programs are demonstrating meaningfully lower cost-per-candidate figures than conventional HTS-led programs, a trend that is reshaping client expectations around discovery efficiency across the segment. The small-molecule segment is expected to maintain its majority position through 2035, supported by the sustained output of novel targeted small-molecule programs and the continued competitive advantage of oral administration in commercial therapeutic markets.

Large-molecule Drugs

Large-molecule drugs represent 41.4% of drug discovery services revenues in 2025, a share that has grown steadily over the preceding decade as the global pharmaceutical pipeline has shifted toward biologics, and one that is projected to increase further through the forecast period as monoclonal antibodies, bispecific constructs, ADCs, and advanced modalities such as mRNA therapeutics and cell and gene therapies scale in development volume. Discovery services for large molecules differ fundamentally from small-molecule workflows: they require specialized biological expression systems, analytical characterization methodologies including size-exclusion chromatography, dynamic light scattering, and bioaffinity assays and increasingly sophisticated in vitro potency and selectivity profiling platforms that replicate the complexity of large-molecule target engagement. WuXi AppTec has built one of the sector's most comprehensive large-molecule discovery service platforms, with dedicated infrastructure for antibody discovery, bispecific engineering, ADC payload-linker optimization, and gene therapy vector characterization across its Shanghai and international facilities.

Pharmaron's cryo-EM structural biology laboratory, commissioned in December 2024, supports large-molecule structure determination for antibody-antigen complex characterization, directly addressing a service gap that previously required pharmaceutical clients to engage separate structural biology specialists. The large-molecule segment within the drug discovery services market is also being shaped by the biosimilar development wave: as multiple blockbuster biologics face imminent loss of exclusivity, both originator and biosimilar developers are generating outsourced analytical and characterization service demand that augments the primary discovery-stage revenue base. Across the value chain, CROs that can offer end-to-end large-molecule services from antibody discovery and cell line development through in vitro potency profiling and early-stage process development are securing longer-duration, higher-value contracts that differentiate them from pure-play service providers capable only of executing discrete assay-stage activities.

By Therapeutic Area

Oncology

Oncology is the largest therapeutic area segment, representing 39.70% of global drug discovery services revenues in 2025, and reflects the sustained concentration of pharmaceutical and biotech pipeline investment in cancer treatments across a broadening range of tumor types and mechanisms. The unmet medical need in oncology where cure rates in many indications remain low despite decades of investment combined with the premium commercial positioning of targeted and immuno-oncology therapies, drives a disproportionate share of active discovery programs toward cancer. From a service standpoint, oncology programs demand specialized CRO capabilities: comprehensive tumor biology platforms, patient-derived xenograft (PDX) and organoid models that replicate tumor heterogeneity, in vitro immuno-oncology assay systems including co-culture T-cell engagement assays, and translational biomarker qualification for companion diagnostic support. Evotec SE and Syngene International maintain dedicated oncology service infrastructure Syngene's oncology biology capabilities include proprietary PDX panels spanning 30+ tumor subtypes while Aurigene Pharmaceutical Services has built an oncology-focused discovery franchise anchored in targeted small-molecule programs and PROTAC degraders.

The ADC segment within oncology discovery is expanding particularly rapidly, with WuXi AppTec and Pharmaron both announcing dedicated ADC characterization capacity additions in 2024–2025 to serve the surge in client programs targeting novel payload-linker combinations. At the segment level, immuno-oncology programs are generating some of the highest per-program outsourcing values in the drug discovery services market, as the complexity of tumor microenvironment biology and the need for multi-parameter immunophenotyping assays raise the technical bar and the associated contract scope for CROs executing these programs. In our Q1 2026 survey covering 280 pharmaceutical R&D directors, oncology was identified as the single therapeutic area most likely to see outsourcing spend increase over the next 24 months, cited by 74% of respondents with active oncology pipeline programs.

Neurology

Neurology accounts for 23.5% of therapeutic area revenues in 2025, driven by the growing volume of CNS discovery programs targeting Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and treatment-resistant depression conditions whose collective disease burden has intensified as global populations age. The neurology segment is technically demanding for CROs relative to many other therapeutic areas: compounds must demonstrate blood-brain barrier penetration, favorable CNS safety pharmacology profiles, and activity in biologically faithful in vitro systems that more accurately replicate neurodegeneration than conventional rodent models. The application of human iPSC-derived neuronal models which can replicate specific disease-relevant cellular phenotypes including tau accumulation, alpha-synuclein aggregation, and synapse loss has become an area of active CRO investment and differentiation, with Evotec SE and Sygnature Discovery offering iPSC-based neurodegeneration assay platforms to pharmaceutical clients seeking higher translational confidence.

CNS programs also tend to generate longer-duration outsourcing relationships due to the iterative nature of brain-penetrant optimization and the need for specialized behavioral pharmacology capabilities in candidate validation. Regulatory filings confirm that CNS-targeted investigational new drug applications have grown as a share of total IND submissions over the past three years, reflecting the depth of active neurology pipelines entering the discovery-to-development transition. The more consequential structural driver over the medium term is the shift toward mechanism-based CNS drug design enabled by advances in structural neurobiology: cryo-EM characterization of ion channel and GPCR targets, combined with AI-guided scaffold optimization, is opening previously intractable CNS target classes to small-molecule programs a development that expands the addressable service opportunity for CROs with integrated structural biology and computational chemistry capabilities.

Infectious Diseases

Infectious diseases account for 16.4% of global drug discovery services revenues in 2025, representing a segment that underwent a structural expansion during and following the COVID-19 pandemic and has since stabilized at an elevated baseline as pharmaceutical companies maintain heightened preparedness-oriented discovery programs. The infectious disease segment spans antibacterial, antiviral, antifungal, and antiparasitic discovery programs, with antiviral discovery remaining elevated in volume as pharmaceutical clients advance broad-spectrum programs against emerging respiratory viruses, RSV, influenza, and persistent targets including HIV and hepatitis. From a service standpoint, infectious disease CRO capabilities must encompass high-containment cell culture systems for replication-competent pathogen work, validated phenotypic and biochemical assay platforms across pathogen classes, and specialized expertise in bacterial resistance mechanisms that inform medicinal chemistry strategy in antibacterial programs.

Eurofins Scientific and Labcorp Drug Development maintain certified biosafety laboratory infrastructure that supports in vitro antiviral and antibacterial screening programs under appropriate containment levels. The global health imperative around antimicrobial resistance which the World Health Organization has classified as one of the most significant threats to public health is driving targeted funding from government agencies and international health organizations into antibacterial discovery programs, providing a policy-driven demand layer that supplements commercial pharmaceutical outsourcing in this segment.² Across the value chain, the infectious disease segment is distinguished by a comparatively higher proportion of public-sector-funded outsourcing relative to other therapeutic areas, as NIH institutes, BARDA, and international health bodies commission discovery programs through CRO contracts to advance candidates against priority pathogen targets independent of commercial pipeline investment cycles.

Diabetes

Diabetes contributes 12.1% of therapeutic area revenues in 2025, underpinned by the global expansion of type 2 diabetes prevalence and the pharmaceutical industry's sustained investment in next-generation metabolic therapeutics that move beyond conventional glycemic control toward broader cardiometabolic benefit profiles. Discovery programs in this area span multiple mechanistic classes including GLP-1 receptor agonists, GIPR co-agonists, SGLT-2 inhibitors, and novel targets in hepatic glucose regulation and adipose tissue metabolism generating diverse outsourcing requirements across chemistry, in vitro metabolic biology, and DMPK profiling. The recent commercial success of GLP-1/GIPR dual agonist programs has intensified competitive discovery activity, with multiple pharmaceutical and biotech companies initiating programs targeting novel incretin biology and oral peptide formulation service areas in which CROs with peptide chemistry expertise, including Sai Life Sciences and Aragen Life Sciences, are positioned to participate.

In vitro pharmacology platforms specific to metabolic diseases including primary hepatocyte assays for glucose metabolism, adipocyte differentiation systems, and pancreatic beta-cell toxicity models represent differentiated capabilities for CROs serving this segment, and several mid-tier providers have invested in dedicated metabolic disease biology infrastructure to capture the outsourcing flow from this growing indication class. The diabetes discovery segment is further supported by the expansion of metabolic disease indication scope: GLP-1-based mechanisms are under active investigation for NASH, chronic kidney disease, and cardiovascular risk reduction, broadening the addressable drug discovery services market beyond core diabetes programs and generating multi-indication outsourcing demand from pharmaceutical clients managing broad cardiometabolic pipelines.

Other Therapeutic Areas

Other therapeutic areas collectively account for 8.30% of global drug discovery services revenues in 2025, encompassing a heterogeneous set of disease indications including rare and orphan diseases, autoimmune and inflammatory conditions, cardiovascular disease, respiratory disorders, and dermatology. While individually smaller in revenue contribution, these areas carry strategic importance for CROs due to their technical specialization requirements and the premium contract values that complex programs in rare and orphan disease typically generate. Rare disease discovery programs which account for a growing fraction of total FDA novel approvals and benefit from accelerated regulatory pathways including Orphan Drug Designation drive demand for highly specialized CRO capabilities in genetic target validation, biomarker-driven patient stratification, and the use of disease-specific in vitro and in vivo model systems.

Autoimmune and inflammatory disease discovery remains an active outsourcing category, with demand concentrated in the development of next-generation biologics and small-molecule immunomodulators targeting JAK-STAT pathways, cytokine receptors, and complement cascade components. CROs with integrated immunology platforms including primary human immune cell assay systems, cytokine multiplex profiling, and in vivo models of autoimmune pathology serve this segment most competitively. Selvita S.A. has developed specific immunology and inflammation discovery capabilities alongside its oncology and CNS platforms, reflecting the CRO sector's broader trend toward therapeutic area diversification among specialist providers. The long-term trajectory for this segment is positive: as precision medicine approaches extend into autoimmune and rare disease, the per-program service content and associated revenue increases materially, supporting above-average revenue growth relative to the segment's current share.

By End Use

Pharmaceutical & Biotechnology Companies

Pharmaceutical and biotechnology companies are the dominant end-user segment, accounting for 68.8% of global drug discovery services revenues in 2025. This share reflects the structural reality that pharmaceutical and biotech organizations are the primary generators of drug discovery programs and the primary buyers of outsourced discovery services, engaging CROs across all stages of the discovery workflow to supplement internal capabilities, accelerate program timelines, and manage R&D cost structures. Within this broad end-user category, large multinational pharmaceutical companies and mid-size biotechs exhibit distinct outsourcing profiles: large pharma companies tend to engage CROs under preferred-provider frameworks for specific service lines medicinal chemistry, DMPK, in vivo efficacy while maintaining internal infrastructure for strategic program management and candidate selection. Mid-size and emerging biotech companies, which now account for a majority of novel clinical pipeline entries globally, rely on CROs for full-service discovery execution, engaging external partners from target validation through IND filing with lean internal teams focused on program strategy and investor communication.

PhRMA data confirms that US pharmaceutical companies alone invested over USD 102 billion in R&D in 2023, establishing the scale of the demand base that underpins outsourcing to CROs. The consolidation of outsourcing relationships in which pharmaceutical companies direct an increasing share of their external spend toward two to three preferred CRO partners rather than distributing it across fragmented transactional vendors is elevating per-client revenue at leading CROs and deepening the commercial relationships that characterize the top tier of the drug discovery services market. Of greater strategic consequence over the medium term is the emergence of risk-sharing contract models including milestone-linked and co-development arrangements in which CROs participate economically in program outcomes rather than operating purely on a fee-for-service basis, aligning incentive structures and deepening integration between pharmaceutical clients and their CRO partners.

Contract Research Organizations

Contract research organization as end users represent 23.50% of global drug discovery services revenues in 2025, capturing outsourcing flows where CROs subcontract specialized capabilities to other CROs or engage in collaborative service delivery arrangements. This segment reflects the increasingly networked structure of the CRO industry: as drug discovery programs grow in technical complexity and geographic scope, no single CRO commands all necessary capabilities in-house, creating a structured sub-contracting market in which specialist CROs provide niche services cryo-EM structural biology, advanced computational chemistry, specialized in vitro biology assays to larger platform CROs on behalf of end pharmaceutical clients. The second-order effect is a qualitative shift in how leading CROs compete: the ability to curate and manage a high-quality partner network is becoming a competitive differentiator alongside direct technical capability, as pharmaceutical clients increasingly evaluate CROs on the breadth of integrated solutions they can deliver rather than the scope of capabilities they own outright.

A second end-use dimension within this segment is academic and public-sector drug discovery programs including NIH-funded institutes, academic drug discovery centers, and government-mandated pandemic preparedness programs which engage CRO services on a project or FTE basis to advance early-stage discovery programs that originate outside the commercial pharmaceutical sector. Sygnature Discovery and BioDuro-Sundia have established specific engagement models to serve academic and public sector clients, offering flexible contract structures that accommodate the funding cycles and governance requirements of non-commercial research organizations. This segment is expected to grow through the forecast period as both CRO sub-contracting and academic drug discovery outsourcing scale with overall market expansion.

Other End Users

Other end users account for 7.7% of global drug discovery services revenues in 2025, encompassing a range of non-pharmaceutical buyers including agrochemical companies, cosmetics and personal care developers, chemical manufacturers conducting biological screening programs, and medical device companies engaged in pharmaceutical-adjacent research. Within this category, agrochemical companies represent the most material demand segment: the discovery of novel pesticidal or herbicidal active ingredients shares methodological overlap with pharmaceutical drug discovery including target identification, compound library screening, and in vitro ADMET profiling creating addressable outsourcing demand for CROs that have adapted their pharmaceutical service platforms to agrochemical clients. Companies including Eurofins Scientific and Charles River Laboratories serve this extended buyer segment through dedicated agrochemical and environmental testing divisions that leverage the same laboratory infrastructure supporting pharmaceutical discovery programs.

The medical device and diagnostics sub-segment, while currently small, is growing in relevance as combination products which incorporate both a pharmaceutical agent and a device component require integrated discovery and characterization services that straddle the pharmaceutical and device regulatory frameworks. At the segment level, the other end-user category is expected to grow at a modest rate relative to the pharmaceutical and CRO segments, reflecting the more limited scale of non-pharmaceutical demand for dedicated drug discovery services. The more consequential long-term development within this segment is the broadening of agrochemical outsourcing scope: as environmental sustainability requirements and regulatory pressure on legacy chemistries intensify globally, agrochemical companies are investing in novel mode-of-action discovery programs that require the same target-based and phenotypic screening capabilities that CROs have built primarily for pharmaceutical clients.

By Region

North America Drug Discovery Services Market

North America is the largest regional market, accounting for 45.56% of global drug discovery services revenues in 2025, anchored by the United States' unmatched concentration of pharmaceutical and biotech companies, extensive NIH-funded research infrastructure, and a regulatory environment governed by the US FDA that sets global standards for drug discovery and development. The FDA Modernization Act 2.0, enacted in late 2022, reduced mandatory animal testing requirements for investigational new drug applications, structurally expanding the addressable market for alternative model-based discovery services including organ-on-a-chip platforms, advanced in vitro systems, and computational safety models. PhRMA data indicates that US-based pharmaceutical companies invested over USD 102 billion in R&D in 2023, providing a broad and durable demand base for contract discovery services. Canada contributes meaningfully to the regional drug discovery services market through its life sciences clusters in Toronto and Montréal, where academic-CRO collaboration programs have attracted investment from Labcorp Drug Development and Charles River Laboratories, supporting early-stage discovery work in oncology and immunology. In March 2025, Charles River Laboratories entered into a multi-year strategic partnership with a North American pharmaceutical company to provide integrated discovery and safety assessment services under a preferred-provider framework, illustrating the consolidation trend that is concentrating outsourcing spend among top-tier platform CROs.

Europe Drug Discovery Services Market

Europe accounts for 25.90% of the global market, with Germany, the United Kingdom, Switzerland, and Belgium serving as the primary commercial hubs. Evotec SE, headquartered in Hamburg, Germany, operates one of Europe's most integrated drug discovery platforms, combining AI-driven target identification with large-scale compound synthesis and preclinical biology across multiple European sites and had established over 50 co-discovery programs with global pharmaceutical partners by early 2025. The European Medicines Agency's Innovation Deals framework has created a structured mechanism for early scientific dialogue on novel discovery modalities, reducing regulatory uncertainty for CROs introducing new service technologies into EU markets. The EU4Health Programme (2021–2027), supported by EUR 5.1 billion in committed funding, has directed capital toward pharmaceutical R&D capacity building across EU member states, further underpinning the European market's medium-term growth trajectory.^{[4]European Commission, ec.europa.eu} Selvita S.A., operating from Kraków, Poland, has expanded its medicinal chemistry and biology services platform in part through EU-funded research partnerships, illustrating the emergence of Central Europe as a meaningful secondary hub within the broader European landscape. Sygnature Discovery opened an expanded medicinal chemistry laboratory at its Nottingham, United Kingdom site in July 2024, adding 25 additional synthetic chemistry positions to accommodate growing outsourced program volumes.

Asia Pacific Drug Discovery Services Market

Asia Pacific represents 22.5% of global market revenues and is the fastest-growing region, driven by expanding CRO infrastructure in China and India, government-supported pharmaceutical innovation policies, and a deepening talent base in medicinal chemistry and structural biology. China's National Medical Products Administration (NMPA) has undertaken substantial regulatory modernization since 2017, aligning submission requirements more closely with ICH guidelines and accelerating review timelines for novel drug applications increasing the commercial attractiveness of China-based CRO services to global pharmaceutical clients. WuXi AppTec, headquartered in Shanghai, operates one of the world's largest integrated drug discovery platforms, spanning chemistry, biology, ADMET, and safety assessment across 30+ sites in China and internationally, with dedicated ADC characterization capacity additions announced in 2024–2025 to serve the surge in oncology biologics programs. In India, Syngene International operating from its Biocon Park campus in Bengaluru inaugurated a dedicated large-molecule research block in January 2025, serving global pharma clients under multi-year integrated discovery agreements. India's Production-Linked Incentive (PLI) scheme for pharmaceuticals, supported by INR 15,000 crore in government funding, is further stimulating domestic pharmaceutical R&D capacity and expanding the local demand base for CRO services, positioning India as a structurally important growth market within the Asia Pacific drug discovery services landscape.^{[5]Ministry of Chemicals and Fertilizers, Government of India, chemicals.nic.in}

Drug Discovery Services Market Share

The global market exhibits moderate concentration. The top five companies Charles River Laboratories International, WuXi AppTec, Pharmaron Beijing, Labcorp Drug Development, and Evotec SE collectively hold approximately 38% of global revenues in 2025. Charles River Laboratories maintains the leading position at approximately 14% market share, underpinned by its broad integrated service platform, global geographic footprint, and established relationships across the world's largest pharmaceutical companies. The remaining four top-tier players hold between 4% and 8% share individually, reflecting the structural differentiation that has emerged between platform CROs offering integrated discovery-through-IND-filing capabilities and specialized providers focused on specific service lines such as computational chemistry, in vitro biologics, or structural biology.

The competitive landscape is further shaped by regional scale dynamics. Chinese CROs, led by WuXi AppTec and Pharmaron, have built globally competitive platforms at cost structures that allow them to serve international pharma clients while simultaneously supporting domestic pharmaceutical innovation. This dual-market positioning has allowed both companies to grow revenues faster than North American and European peers in recent years, driving share gains. At the same time, legislative discussions in the United States including the proposed BIOSECURE Act, which would restrict federal funding to companies with ties to certain China-based CROs have introduced strategic uncertainty for pharmaceutical clients reliant on China-based outsourcing, prompting some to assess geographic diversification of their CRO portfolios toward India, Europe, and South Korea. This dynamic is particularly consequential for the drug discovery services market share distribution over the medium term, as pharmaceutical procurement strategies realign across geographies.

M&A activity has been a consistent feature of competitive dynamics, as leading CROs expand capabilities and geographic reach through strategic acquisitions. Charles River Laboratories has executed multiple acquisitions to extend its platform into areas including cell therapy development and in silico modeling. Thermo Fisher Scientific's integration of PPD created a broader clinical-preclinical services continuum, extending the company's relevance from early discovery through Phase III. Conversations with six industry veterans during our Q4 2025 expert panel converged on a clear strategic point: the next phase of competitive differentiation will center on proprietary data assets specifically, biological and chemical datasets that enable CROs to train more accurate AI models than competitors relying primarily on public databases and the ability to demonstrate measurable improvement in translational success rates for outsourced programs.

The roughly 62% of market revenues outside the top five is distributed across a fragmented landscape of specialized and regional CROs, including Eurofins Scientific, Syngene International, Curia Global, Sai Life Sciences, and Aragen Life Sciences. These mid-tier players compete on specialization, geographic proximity to client research centers, and cost structure, and several have established compelling positions in high-value niches such as PROTAC degrader chemistry, covalent drug design, RNA-targeted therapeutics, and advanced bioanalytical services areas where technical depth rather than platform breadth determines client selection. The long-term share trajectory of the market favors continued consolidation at the top tier through M&A activity, while the specialist segment expands in absolute revenue terms as pharmaceutical pipelines grow in therapeutic area diversity and modality complexity.

Drug Discovery Services Market Companies

Major players operating in the market are: Charles River Laboratories International, Inc.; WuXi AppTec Co., Ltd.; Pharmaron Beijing Co., Ltd.; Labcorp Drug Development; Evotec SE; Thermo Fisher Scientific Inc. (PPD); Eurofins Scientific SE; Syngene International Limited; Curia Global, Inc.; Sai Life Sciences Limited; Aragen Life Sciences Ltd.; Sygnature Discovery Ltd.; BioDuro-Sundia; Aurigene Pharmaceutical Services Ltd.; and Selvita S.A.

Charles River Laboratories International, Inc. maintains the largest global footprint among drug discovery CROs, with operations spanning discovery chemistry, in vivo biology, safety assessment, and regulatory consulting across North America, Europe, and Asia. Its integrated service model covering the continuum from early target identification through GLP toxicology and IND filing allows pharmaceutical clients to advance programs within a single CRO relationship, reducing handoff complexity and timeline risk. The company has expanded its computational chemistry, digital pathology, and cell therapy capabilities through targeted acquisitions, reinforcing its position in technology-enabled and biologic discovery. Our Q1 2026 survey data confirms that Charles River Laboratories is the most frequently cited preferred-provider partner among large pharma respondents, with 41% of surveyed North American pharmaceutical R&D directors naming the company as their primary integrated discovery CRO.

WuXi AppTec Co., Ltd. operates one of the largest and most diversified drug discovery platforms globally, with chemistry, biology, and advanced therapy capabilities across more than 30 research and manufacturing sites. The company serves clients across pharmaceutical, biotech, and medical device sectors, offering services from small-molecule synthesis and biologics discovery through cell and gene therapy development. Its cost-competitive positioning combined with high-throughput capacity has made WuXi a preferred partner for global pharmaceutical companies seeking large-volume compound synthesis and screening programs. WuXi announced dedicated ADC characterization capacity additions in 2024–2025 to serve the surge in oncology biologics client programs targeting novel payload-linker combinations.

Pharmaron Beijing Co., Ltd. has established itself as a leading integrated CRO with particular strength in medicinal chemistry and in vitro biology services. Operating dedicated sites in China, the United Kingdom, and the United States, Pharmaron offers clients geographic diversification within a single outsourcing relationship. Its capabilities span early discovery through preclinical development, with recognized expertise in DMPK, in vitro pharmacology, and cryo-EM-supported structural biology the latter anchored by a new structural biology laboratory commissioned at its Ningbo site in December 2024.

Labcorp Drug Development brings together broad CRO capabilities across preclinical and clinical services, with a discovery offering encompassing central laboratory services, bioanalytical chemistry, and translational biomarker development. Labcorp serves pharmaceutical and biotech clients globally, leveraging its clinical data network to provide an integrated discovery-to-Phase II development pathway. In November 2024, the company announced a strategic expansion of its bioanalytical services capabilities across its European laboratory network, adding large-molecule bioanalysis capacity to serve growing biologics client programs.

Evotec SE, headquartered in Hamburg, Germany, differentiates through its AI-augmented EVOiD drug discovery platform and its extensive network of academic and pharma co-discovery partnerships under the "Shared Discovery Engine" model. The company has established dedicated research centers in collaboration with global pharmaceutical companies across specific therapeutic areas, including an Alzheimer's disease-focused co-discovery initiative and multiple oncology-targeted programs. In February 2025, Evotec launched a new AI-augmented CNS drug discovery program in collaboration with a major European academic medical center, targeting novel mechanisms for treatment-resistant depression and related neurological disorders.

Thermo Fisher Scientific Inc. (PPD) provides a broad range of preclinical and clinical services, with discovery support anchored in laboratory sciences and pharmaceutical services divisions. The company's automation-enabled HTS capabilities, advanced bioanalytical platforms, and global regulatory expertise serve pharmaceutical clients at scale across multiple therapeutic areas. In October 2024, Thermo Fisher deployed a next-generation high-throughput screening automation platform at its US discovery facility, increasing compound processing throughput by approximately 40%.

Eurofins Scientific SE operates extensive bioanalytical and in vitro testing capabilities through its pharmaceutical services division, with laboratories across Europe, North America, and Asia. Its services in early ADMET profiling, in vitro safety pharmacology, genomics, and protein characterization support drug discovery programs at multiple development stages. The company opened a dedicated ADMET profiling laboratory in Lyon, France in August 2024, targeting early-stage pharmaceutical clients across Europe.

Syngene International Limited, operating from its Bengaluru, India campus, provides integrated discovery research services to global pharmaceutical clients under dedicated center and FTE-based engagement models. Capabilities span medicinal chemistry, structural biology, in vitro biology, and biologics discovery, including proprietary PDX panels spanning 30+ tumor subtypes for oncology programs. In January 2025, Syngene inaugurated a new biologics discovery block at its Biocon Park campus, expanding large-molecule research capacity.

Curia Global, Inc. focuses on integrated CDMO and discovery chemistry services, offering medicinal chemistry, process chemistry, and API synthesis capabilities across its US and international sites. Its discovery chemistry platform supports hit-to-lead and lead optimization programs for pharmaceutical and biotech clients seeking combined discovery and development support within a single provider relationship.

Sai Life Sciences Limited, headquartered in Hyderabad, India, provides integrated drug discovery services including medicinal chemistry, in vitro biology, and DMPK, supported by laboratory infrastructure in India and the United Kingdom. The company expanded its integrated discovery chemistry and biology facility in Hyderabad in September 2024, adding capacity to support over 30 concurrent drug discovery programs across medicinal chemistry and in vitro biology.

Aragen Life Sciences Ltd. offers integrated discovery chemistry and biology services with recognized strengths in heterocyclic chemistry, biochemical assay development, and in vitro ADMET screening. Headquartered in Hyderabad, Aragen serves mid-size and large pharmaceutical clients in North America and Europe through both FTE-based and project-based engagement structures, with noted capabilities in metabolic disease and peptide chemistry workflows.

Sygnature Discovery Ltd., based in Nottingham, United Kingdom, is a specialist discovery CRO with deep integrated capabilities spanning hit identification, medicinal chemistry, in vitro biology, structural biology, and DMPK. The company opened an expanded medicinal chemistry laboratory at its Nottingham site in July 2024, adding 25 additional synthetic chemistry positions. Sygnature is recognized in the European drug discovery services market for its collaborative scientific engagement model and its application of fragment-based and structure-guided drug design across therapeutic areas.

BioDuro-Sundia provides integrated discovery and development services with combined chemistry and biology capabilities including compound synthesis, biochemical screening, and in vitro and in vivo pharmacology across its North America and China sites. The company serves clients seeking geographic flexibility within a single integrated CRO relationship, with specific engagement models tailored to academic and public sector research organizations.

Aurigene Pharmaceutical Services Ltd. is an India-based CRO with established expertise in oncology and inflammation discovery programs, offering integrated medicinal chemistry and biology services to global pharmaceutical and biotech clients. In June 2024, Aurigene entered a co-discovery agreement with an Asia-headquartered biotech company focused on developing PROTAC-based degrader candidates in oncology, expanding its portfolio of targeted therapy programs.

Selvita S.A., headquartered in Kraków, Poland, provides drug discovery services including medicinal chemistry, structural biology, and in vitro pharmacology, and is recognized as a leading specialist CRO in Central Europe. The company has expanded its service offering through EU-funded research collaborations and partnerships with European biotech companies, and maintains satellite capabilities in the United Kingdom positioning Selvita as a cost-competitive alternative to Western European providers within the regional drug discovery services landscape.

Drug Discovery Services Industry News

• Apr 2025: WuXi AppTec announced expansion of its biology services platform in Shanghai, adding dedicated capacity for antibody-drug conjugate (ADC) discovery and characterization to serve growing global demand for oncology biologics programs.
• Mar 2025: Charles River Laboratories entered into a multi-year strategic partnership with a North American pharmaceutical company to provide integrated discovery and safety assessment services under a preferred-provider framework, consolidating the client's early-stage outsourcing.
• Feb 2025: Evotec SE launched a new AI-augmented CNS drug discovery program in collaboration with a major European academic medical center, targeting novel mechanisms for treatment-resistant depression and related neurological disorders.
• Jan 2025: Syngene International inaugurated a new biologics discovery block at its Biocon Park campus in Bengaluru, India, expanding large-molecule research capacity to support global pharma clients under integrated discovery agreements.
• Dec 2024: Pharmaron Beijing commissioned a new structural biology laboratory at its Ningbo site, equipped with cryo-electron microscopy infrastructure to support structure-based drug design across client oncology and CNS programs.
• Nov 2024: Labcorp Drug Development announced a strategic expansion of its bioanalytical services capabilities across its European laboratory network, adding large-molecule bioanalysis capacity to serve growing biologics client programs.
• Oct 2024: Thermo Fisher Scientific (PPD) deployed a next-generation high-throughput screening automation platform at its US discovery facility, increasing compound processing throughput by approximately 40% and reducing hit confirmation cycle times.
• Sep 2024: Sai Life Sciences Limited opened a new integrated discovery chemistry and biology facility in Hyderabad, India, with capacity to support over 30 concurrent drug discovery programs across medicinal chemistry and in vitro biology.
• Aug 2024: Eurofins Scientific expanded its in vitro ADMET screening services with the launch of a dedicated ADMET profiling laboratory in Lyon, France, targeting early-stage pharmaceutical clients across Europe.
• Jul 2024: Sygnature Discovery opened an expanded medicinal chemistry laboratory at its Nottingham, United Kingdom site, adding 25 additional synthetic chemistry positions to accommodate growing outsourced discovery program volumes.
• Jun 2024: Aurigene Pharmaceutical Services entered a co-discovery agreement with an Asia-headquartered biotech company focused on developing PROTAC-based degrader candidates in oncology, expanding its portfolio of targeted therapy programs.

The drug discovery services market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Process

• Target selection
• Target validation
• Hit-to-lead identification
• Lead optimization
• Candidate validation

Market, By Type

• Chemistry services
• Biological services

Market, By Drug Type

• Small-molecule drugs
• Large-molecule drugs

Market, By Therapeutic Area

• Diabetes
• Neurology
• Oncology
• Infectious diseases
• Other therapeutic areas

Market, By End Use

• Pharmaceutical & biotechnology companies
• Contract Research Organizations
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
• • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE